Lowering blood pressure 2003

Medical Journal of Australia

Volumn 179, Issue 6, 2003, Pages 306-312

  Chalmers, John P ^a   Arnolda, Leonard F ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EXERCISE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE; LOW DRUG DOSE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; SODIUM RESTRICTION; TARGET ORGAN; TREATMENT INDICATION; VASCULAR DISEASE; WEIGHT REDUCTION;

EID: 0141706907     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05554.x     Document Type: Review

References (27)

1. National high blood pressure education program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
2. Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-918.
3. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-1964.
4. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
5. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
6. Chobanian AR, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC VII report. JAMA 2003; 289: 2560-2572.
7. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
8. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization, 2002.
9. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360.
10. Murray CJL, Lauer JA, Hutubessy RCW, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003; 361: 717-725.
11. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
12. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. PROGRESS Collaborative Group. Lancet 2001; 358: 1033-1041.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
14. MRC trial of treatment of mild hypertension: Principal results. Medical Research Council Working Party. BMJ 1985; 291: 97-104.
15. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15: 105-115.
16. Medical Research Council trial of treatment of hypertension in older adults: Principal results. MRC Working Party. BMJ 1992; 304: 405-412.
17. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875-886.
18. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
19. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
20. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
21. Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
22. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
23. Australian comparative outcome trial of angiotensin-converting enzyme inhibitor-and diuretic-based treatment of hypertension in the elderly (ANBP2): Objectives and protocol. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exp Pharmacol Physiol 1997; 24: 188-192.
24. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
25. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903-1913.
26. Blood pressure and cardiovascular disease in the Asia Pacific region. Asian Pacific Cohort Studies Collaboration. J Hypertens 2003; 21: 707-716.
27. Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens 1999; 21: 875-884.